In the tumor model, STAT5 triggers Bcr-Abl mutation, which inhibits GRX1 gene expression, leading to an increase in ROS levels and a decrease in cell viability in chronic myeloid leukemia [61]. The gene discussed is GLRX; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.